nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—MAPT—midbrain—attention deficit hyperactivity disorder	0.0934	0.101	CbGeAlD
Lansoprazole—ATP4A—cardiovascular system—attention deficit hyperactivity disorder	0.0888	0.0958	CbGeAlD
Lansoprazole—MAPT—cerebellum—attention deficit hyperactivity disorder	0.0723	0.0779	CbGeAlD
Lansoprazole—MAPT—brain—attention deficit hyperactivity disorder	0.0587	0.0633	CbGeAlD
Lansoprazole—ATP4A—nervous system—attention deficit hyperactivity disorder	0.057	0.0615	CbGeAlD
Lansoprazole—ATP4A—central nervous system—attention deficit hyperactivity disorder	0.0549	0.0592	CbGeAlD
Lansoprazole—ATP4A—cerebellum—attention deficit hyperactivity disorder	0.0536	0.0579	CbGeAlD
Lansoprazole—ATP4A—brain—attention deficit hyperactivity disorder	0.0436	0.047	CbGeAlD
Lansoprazole—CYP1B1—cardiovascular system—attention deficit hyperactivity disorder	0.0354	0.0381	CbGeAlD
Lansoprazole—CYP2C9—cardiovascular system—attention deficit hyperactivity disorder	0.024	0.0259	CbGeAlD
Lansoprazole—CYP1B1—nervous system—attention deficit hyperactivity disorder	0.0227	0.0245	CbGeAlD
Lansoprazole—CYP1B1—central nervous system—attention deficit hyperactivity disorder	0.0219	0.0236	CbGeAlD
Lansoprazole—CYP1B1—cerebellum—attention deficit hyperactivity disorder	0.0214	0.023	CbGeAlD
Lansoprazole—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.0213	0.023	CbGeAlD
Lansoprazole—ABCG2—midbrain—attention deficit hyperactivity disorder	0.0206	0.0222	CbGeAlD
Lansoprazole—CYP1B1—brain—attention deficit hyperactivity disorder	0.0173	0.0187	CbGeAlD
Lansoprazole—CYP1A1—nervous system—attention deficit hyperactivity disorder	0.016	0.0173	CbGeAlD
Lansoprazole—ABCG2—cerebellum—attention deficit hyperactivity disorder	0.0159	0.0172	CbGeAlD
Lansoprazole—CYP1A1—central nervous system—attention deficit hyperactivity disorder	0.0154	0.0167	CbGeAlD
Lansoprazole—ABCB1—forebrain—attention deficit hyperactivity disorder	0.0154	0.0166	CbGeAlD
Lansoprazole—CYP2C8—brain—attention deficit hyperactivity disorder	0.0133	0.0143	CbGeAlD
Lansoprazole—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.013	0.014	CbGeAlD
Lansoprazole—ABCG2—brain—attention deficit hyperactivity disorder	0.0129	0.0139	CbGeAlD
Lansoprazole—CYP1A1—brain—attention deficit hyperactivity disorder	0.0123	0.0132	CbGeAlD
Lansoprazole—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.0118	0.0127	CbGeAlD
Lansoprazole—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.0116	0.0125	CbGeAlD
Lansoprazole—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.0113	0.0122	CbGeAlD
Lansoprazole—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.0112	0.012	CbGeAlD
Lansoprazole—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.0109	0.0118	CbGeAlD
Lansoprazole—ABCB1—midbrain—attention deficit hyperactivity disorder	0.0101	0.0109	CbGeAlD
Lansoprazole—CYP2D6—brain—attention deficit hyperactivity disorder	0.00885	0.00955	CbGeAlD
Lansoprazole—ABCB1—nervous system—attention deficit hyperactivity disorder	0.00833	0.00899	CbGeAlD
Lansoprazole—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.00802	0.00865	CbGeAlD
Lansoprazole—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.00784	0.00846	CbGeAlD
Lansoprazole—ABCB1—brain—attention deficit hyperactivity disorder	0.00637	0.00687	CbGeAlD
Lansoprazole—ATP4B—Ion channel transport—GABRQ—attention deficit hyperactivity disorder	0.0057	0.0784	CbGpPWpGaD
Lansoprazole—ATP4A—Ion channel transport—GABRQ—attention deficit hyperactivity disorder	0.00508	0.0699	CbGpPWpGaD
Lansoprazole—MAPT—Alzheimers Disease—CACNA1C—attention deficit hyperactivity disorder	0.00291	0.04	CbGpPWpGaD
Lansoprazole—CYP1B1—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00235	0.0322	CbGpPWpGaD
Lansoprazole—ABCG2—Fluoropyrimidine Activity—DPYD—attention deficit hyperactivity disorder	0.00213	0.0293	CbGpPWpGaD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00208	0.0286	CbGpPWpGaD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00198	0.0273	CbGpPWpGaD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00185	0.0255	CbGpPWpGaD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00177	0.0243	CbGpPWpGaD
Lansoprazole—CYP1B1—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.00159	0.0219	CbGpPWpGaD
Lansoprazole—CYP1A2—Methylation—COMT—attention deficit hyperactivity disorder	0.00147	0.0203	CbGpPWpGaD
Lansoprazole—CYP1A1—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00144	0.0199	CbGpPWpGaD
Lansoprazole—MAPT—BDNF signaling pathway—BDNF—attention deficit hyperactivity disorder	0.00114	0.0157	CbGpPWpGaD
Lansoprazole—CYP4A11—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00112	0.0154	CbGpPWpGaD
Lansoprazole—MAPT—Kit receptor signaling pathway—EP300—attention deficit hyperactivity disorder	0.00104	0.0143	CbGpPWpGaD
Lansoprazole—MAPT—Notch Signaling Pathway—EP300—attention deficit hyperactivity disorder	0.00102	0.014	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—BDNF—attention deficit hyperactivity disorder	0.00101	0.0139	CbGpPWpGaD
Lansoprazole—CYP1A1—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.000979	0.0135	CbGpPWpGaD
Lansoprazole—CYP2C18—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000977	0.0134	CbGpPWpGaD
Lansoprazole—CYP1A1—Oxidative Stress—MAOA—attention deficit hyperactivity disorder	0.000953	0.0131	CbGpPWpGaD
Lansoprazole—CYP1A2—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.000921	0.0127	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.00091	0.0125	CbGpPWpGaD
Lansoprazole—CYP4A11—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.0009	0.0124	CbGpPWpGaD
Lansoprazole—CYP4A11—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.000802	0.011	CbGpPWpGaD
Lansoprazole—CYP2C19—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.000801	0.011	CbGpPWpGaD
Lansoprazole—CYP2D6—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.000737	0.0101	CbGpPWpGaD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000724	0.00995	CbGpPWpGaD
Lansoprazole—CYP1B1—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000721	0.0099	CbGpPWpGaD
Lansoprazole—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.000711	0.00977	CbGpPWpGaD
Lansoprazole—CYP2C18—FOXA1 transcription factor network—EP300—attention deficit hyperactivity disorder	0.000667	0.00917	CbGpPWpGaD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000645	0.00887	CbGpPWpGaD
Lansoprazole—CYP1A2—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.000624	0.00858	CbGpPWpGaD
Lansoprazole—CYP4A11—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000598	0.00822	CbGpPWpGaD
Lansoprazole—CYP4A11—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000594	0.00816	CbGpPWpGaD
Lansoprazole—ABCG2—HIF-2-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.00055	0.00756	CbGpPWpGaD
Lansoprazole—CYP2C18—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000523	0.00719	CbGpPWpGaD
Lansoprazole—CYP2C18—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000519	0.00714	CbGpPWpGaD
Lansoprazole—CYP2C18—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000516	0.00709	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.000475	0.00653	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.000475	0.00653	CbGpPWpGaD
Lansoprazole—CYP1A1—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000444	0.0061	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000433	0.00595	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000413	0.00567	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000408	0.0056	CbGpPWpGaD
Lansoprazole—CYP2C8—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000407	0.00559	CbGpPWpGaD
Lansoprazole—CYP1B1—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000386	0.0053	CbGpPWpGaD
Lansoprazole—CYP1B1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000383	0.00526	CbGpPWpGaD
Lansoprazole—CYP1B1—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00038	0.00523	CbGpPWpGaD
Lansoprazole—CYP4A11—PPARA activates gene expression—EP300—attention deficit hyperactivity disorder	0.000367	0.00504	CbGpPWpGaD
Lansoprazole—CYP2C19—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000363	0.00499	CbGpPWpGaD
Lansoprazole—CYP4A11—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—attention deficit hyperactivity disorder	0.000359	0.00493	CbGpPWpGaD
Lansoprazole—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000334	0.00459	CbGpPWpGaD
Lansoprazole—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000331	0.00455	CbGpPWpGaD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.000324	0.00445	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.000292	0.00402	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.000292	0.00402	CbGpPWpGaD
Lansoprazole—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000283	0.00389	CbGpPWpGaD
Lansoprazole—CYP1A2—Phase II conjugation—COMT—attention deficit hyperactivity disorder	0.000259	0.00356	CbGpPWpGaD
Lansoprazole—CYP4A11—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—attention deficit hyperactivity disorder	0.000247	0.0034	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000245	0.00336	CbGpPWpGaD
Lansoprazole—CYP1A1—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000237	0.00326	CbGpPWpGaD
Lansoprazole—CYP1A1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000236	0.00324	CbGpPWpGaD
Lansoprazole—CYP1A1—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000234	0.00322	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000234	0.00322	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000223	0.00307	CbGpPWpGaD
Lansoprazole—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000218	0.003	CbGpPWpGaD
Lansoprazole—CYP2C8—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000218	0.00299	CbGpPWpGaD
Lansoprazole—CYP2C8—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000216	0.00297	CbGpPWpGaD
Lansoprazole—CYP2C8—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000215	0.00295	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000214	0.00294	CbGpPWpGaD
Lansoprazole—CYP2C19—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000194	0.00267	CbGpPWpGaD
Lansoprazole—CYP2C19—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000193	0.00265	CbGpPWpGaD
Lansoprazole—CYP2C19—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000192	0.00263	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.000186	0.00256	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.000186	0.00256	CbGpPWpGaD
Lansoprazole—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000179	0.00246	CbGpPWpGaD
Lansoprazole—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000177	0.00244	CbGpPWpGaD
Lansoprazole—CYP2C9—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000177	0.00243	CbGpPWpGaD
Lansoprazole—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000176	0.00242	CbGpPWpGaD
Lansoprazole—CYP2C9—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000176	0.00242	CbGpPWpGaD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.000175	0.0024	CbGpPWpGaD
Lansoprazole—CYP2C9—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000175	0.0024	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000169	0.00232	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000169	0.00232	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.000167	0.0023	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000166	0.00228	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000158	0.00217	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000154	0.00212	CbGpPWpGaD
Lansoprazole—CYP1A2—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000151	0.00208	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000151	0.00207	CbGpPWpGaD
Lansoprazole—CYP1A2—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00015	0.00207	CbGpPWpGaD
Lansoprazole—CYP1A2—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000149	0.00205	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000148	0.00203	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000148	0.00203	CbGpPWpGaD
Lansoprazole—CYP1A1—PPARA activates gene expression—EP300—attention deficit hyperactivity disorder	0.000146	0.002	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000145	0.002	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000143	0.00197	CbGpPWpGaD
Lansoprazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—attention deficit hyperactivity disorder	0.000142	0.00196	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000135	0.00186	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000135	0.00186	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000129	0.00177	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000118	0.00162	CbGpPWpGaD
Lansoprazole—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000117	0.00161	CbGpPWpGaD
Lansoprazole—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000116	0.00159	CbGpPWpGaD
Lansoprazole—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000115	0.00158	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000112	0.00154	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000109	0.0015	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000109	0.0015	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000107	0.00147	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—COMT—attention deficit hyperactivity disorder	0.000102	0.00141	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000102	0.0014	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	9.95e-05	0.00137	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—TPH2—attention deficit hyperactivity disorder	9.9e-05	0.00136	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CACNB2—attention deficit hyperactivity disorder	9.9e-05	0.00136	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	9.85e-05	0.00135	CbGpPWpGaD
Lansoprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—attention deficit hyperactivity disorder	9.82e-05	0.00135	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—DPYD—attention deficit hyperactivity disorder	9.74e-05	0.00134	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	9.71e-05	0.00133	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	9.05e-05	0.00124	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—COMT—attention deficit hyperactivity disorder	8.94e-05	0.00123	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ADRA2C—attention deficit hyperactivity disorder	8.9e-05	0.00122	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—MAOA—attention deficit hyperactivity disorder	8.88e-05	0.00122	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—SNAP25—attention deficit hyperactivity disorder	8.7e-05	0.0012	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	8.28e-05	0.00114	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	8.14e-05	0.00112	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ADRA2C—attention deficit hyperactivity disorder	7.94e-05	0.00109	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—SNAP25—attention deficit hyperactivity disorder	7.91e-05	0.00109	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	7.75e-05	0.00107	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	7.53e-05	0.00104	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	7.48e-05	0.00103	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	7.31e-05	0.001	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	7.24e-05	0.000996	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—TPH2—attention deficit hyperactivity disorder	6.7e-05	0.000921	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CACNB2—attention deficit hyperactivity disorder	6.7e-05	0.000921	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—COMT—attention deficit hyperactivity disorder	6.59e-05	0.000906	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—DPYD—attention deficit hyperactivity disorder	6.59e-05	0.000906	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—MAOA—attention deficit hyperactivity disorder	6.55e-05	0.0009	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	6.35e-05	0.000872	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	6.19e-05	0.000851	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—TPH2—attention deficit hyperactivity disorder	6.14e-05	0.000844	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CACNB2—attention deficit hyperactivity disorder	6.14e-05	0.000844	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	6.13e-05	0.000842	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—DPYD—attention deficit hyperactivity disorder	6.04e-05	0.000831	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—COMT—attention deficit hyperactivity disorder	6e-05	0.000824	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—MAOA—attention deficit hyperactivity disorder	5.96e-05	0.000819	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CACNA1C—attention deficit hyperactivity disorder	5.62e-05	0.000772	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CACNB2—attention deficit hyperactivity disorder	5.48e-05	0.000754	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—TPH2—attention deficit hyperactivity disorder	5.48e-05	0.000754	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—DPYD—attention deficit hyperactivity disorder	5.4e-05	0.000741	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—SNAP25—attention deficit hyperactivity disorder	5.36e-05	0.000736	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	5.35e-05	0.000736	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	5.35e-05	0.000736	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	5.27e-05	0.000724	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5.1e-05	0.000701	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	5.04e-05	0.000693	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	5.04e-05	0.000693	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CACNA1C—attention deficit hyperactivity disorder	5.02e-05	0.000689	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	5e-05	0.000687	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	5e-05	0.000687	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	4.96e-05	0.000682	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	4.92e-05	0.000676	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.91e-05	0.000675	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	4.9e-05	0.000673	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	4.78e-05	0.000657	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ADRA2A—attention deficit hyperactivity disorder	4.68e-05	0.000643	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	4.61e-05	0.000634	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	4.57e-05	0.000629	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—EP300—attention deficit hyperactivity disorder	4.39e-05	0.000603	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.38e-05	0.000603	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.28e-05	0.000588	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	4.27e-05	0.000587	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	4.27e-05	0.000587	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	4.2e-05	0.000578	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ADRA2A—attention deficit hyperactivity disorder	4.17e-05	0.000574	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	4.07e-05	0.00056	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—COMT—attention deficit hyperactivity disorder	4.06e-05	0.000558	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.03e-05	0.000554	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—MAOA—attention deficit hyperactivity disorder	4.03e-05	0.000554	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	4e-05	0.000549	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	3.91e-05	0.000537	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.91e-05	0.000537	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.84e-05	0.000528	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—EP300—attention deficit hyperactivity disorder	3.84e-05	0.000527	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.81e-05	0.000523	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—COMT—attention deficit hyperactivity disorder	3.72e-05	0.000512	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—MAOA—attention deficit hyperactivity disorder	3.7e-05	0.000508	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	3.58e-05	0.000493	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.42e-05	0.000469	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—COMT—attention deficit hyperactivity disorder	3.32e-05	0.000457	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—MAOA—attention deficit hyperactivity disorder	3.3e-05	0.000453	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	3.3e-05	0.000453	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.3e-05	0.000453	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.25e-05	0.000447	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	3.24e-05	0.000446	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	3.24e-05	0.000446	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	3.22e-05	0.000443	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	3.2e-05	0.00044	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	3.06e-05	0.00042	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	3.03e-05	0.000417	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	3.03e-05	0.000416	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.02e-05	0.000415	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	3.01e-05	0.000413	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	2.92e-05	0.000401	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—EP300—attention deficit hyperactivity disorder	2.83e-05	0.000389	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.64e-05	0.000362	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	2.59e-05	0.000356	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—EP300—attention deficit hyperactivity disorder	2.57e-05	0.000354	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	2.57e-05	0.000353	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.51e-05	0.000345	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	2.49e-05	0.000343	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	2e-05	0.000275	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	1.98e-05	0.000273	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—EP300—attention deficit hyperactivity disorder	1.74e-05	0.000239	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—EP300—attention deficit hyperactivity disorder	1.6e-05	0.000219	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—EP300—attention deficit hyperactivity disorder	1.42e-05	0.000196	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	1.39e-05	0.000191	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	1.31e-05	0.00018	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	1.3e-05	0.000179	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	1.11e-05	0.000153	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	8.57e-06	0.000118	CbGpPWpGaD
